Capivasertib, a protein kinase B (AKT) inhibitor, has demonstrated robust efficacy against hormone receptor–positive, human epidermal growth factor receptor type 2–negative advanced breast cancer, particularly in patients with AKT pathway mutations. The gene discussed is AKT1; the disease is breast carcinoma.